CEACAM5 and cancer: In specific relation to the development of cancer vaccines, several groups are currently assessing the immunologic and clinical activity of Ad vectors expressing a variety of TAAs, including prostate serum antigen (PSA), HER-2/neu, carcinoembryonic antigen (CEA) and telomerase (hTERT) [91].